We are live on ! Find out more
FLAM

First Light Asset Management Portfolio holdings

AUM $1.12B
1-Year Est. Return 114.45%
This Fund
S&P 500
This Quarter Est. Return
+12.57%
1 Year Est. Return
+114.45%
3 Year Est. Return
+266.49%
5 Year Est. Return
+454.92%
10 Year Est. Return
+8,470.94%
AUM
$1.28B
AUM Growth
+$165M
Cap. Flow
+$73.1M
Cap. Flow %
5.73%
Top 10 Hldgs %
52.86%
Holding
80
New
6
Increased
21
Reduced
22
Closed
1

Top Buys

Rank Stock Value
1
BCYC
Bicycle Therapeutics
BCYC
+$24.2M
2
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$18.2M
3
TELA icon
TELA Bio
TELA
+$17.6M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$16.4M
5
OM icon
Outset Medical
OM
+$13M

Top Sells

Rank Stock Value
1
BLU
BELLUS Health Inc.
BLU
+$21.7M
2
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$14.6M
3
KRYS icon
Krystal Biotech
KRYS
+$9.67M
4
KROS icon
Keros Therapeutics
KROS
+$7.77M
5
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$7.48M

Sector Composition

Rank Sector Weight
1 Healthcare 94.83%
2 Communication Services 5.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FMS icon
51
Fresenius Medical Care
FMS
$13.8B
$466K 0.04%
19,490
– –
ENOV icon
52
Enovis
ENOV
$1.68B
$462K 0.04%
7,203
– –
NVS icon
53
Novartis
NVS
$297B
$416K 0.03%
4,123
– –
SNY icon
54
Sanofi
SNY
$103B
$416K 0.03%
7,711
– –
TAK icon
55
Takeda Pharmaceutical
TAK
$54.6B
$403K 0.03%
25,630
– –
HUM icon
56
Humana
HUM
$43.7B
$397K 0.03%
888
– –
ELV icon
57
Elevance Health
ELV
$81.5B
$394K 0.03%
886
– –
CNC icon
58
Centene
CNC
$30.7B
$372K 0.03%
5,521
– –
MDT icon
59
Medtronic
MDT
$109B
$369K 0.03%
4,188
– –
GSK icon
60
GSK
GSK
$104B
$358K 0.03%
10,058
– –
JNJ icon
61
Johnson & Johnson
JNJ
$618B
$358K 0.03%
2,161
– –
QDEL icon
62
QuidelOrtho
QDEL
$1.14B
$353K 0.03%
4,257
– –
EXEL icon
63
Exelixis
EXEL
$13.3B
$352K 0.03%
18,445
– –
BAY
64
DELISTED
BAYER AG SPONS ADR
BAY
$352K 0.03%
25,475
– –
HCA icon
65
HCA Healthcare
HCA
$87.2B
$352K 0.03%
1,160
– –
GILD icon
66
Gilead Sciences
GILD
$162B
$349K 0.03%
4,526
– –
VTRS icon
67
Viatris
VTRS
$20.4B
$329K 0.03%
33,010
– –
XRAY icon
68
Dentsply Sirona
XRAY
$2.68B
$329K 0.03%
8,228
– –
BIIB icon
69
Biogen
BIIB
$30B
$312K 0.02%
1,096
– –
QGEN icon
70
Qiagen
QGEN
$8.54B
$311K 0.02%
6,518
– –
PDCO
71
DELISTED
Patterson Companies, Inc.
PDCO
$308K 0.02%
9,264
– –
AVTR icon
72
Avantor
AVTR
$9.32B
$300K 0.02%
14,596
– –
IART icon
73
Integra LifeSciences
IART
$1.29B
$299K 0.02%
7,261
– –
UTHR icon
74
United Therapeutics
UTHR
$25.8B
$297K 0.02%
1,345
– –
LH icon
75
Labcorp
LH
$25B
$294K 0.02%
1,418
– –
1 2
3
4

Similar funds

AIM
Advyzon Investment Management Lisle, Illinois $1.12B AUM 22.08% 1-Year Est. Return
MTCM
Mint Tower Capital Management Amsterdam, Netherlands $1.12B AUM 19.06% 1-Year Est. Return
CNC
Canandaigua National Corp Canandaigua, New York $1.12B AUM
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
RIM
Rockbridge Investment Management Syracuse, New York $1.11B AUM 13.62% 1-Year Est. Return
CT
Caldwell Trust Venice, Florida $1.12B AUM 21.31% 1-Year Est. Return
SL
Salomon & Ludwin Richmond, Virginia $1.12B AUM 14.38% 1-Year Est. Return
HH
Hilltop Holdings Dallas, Texas $1.11B AUM 24.7% 1-Year Est. Return

First Light Asset Management's Q2 2023 Portfolio in Review

As of Q2 2023, First Light Asset Management held 80 positions worth $1.28B, up 15% from $1.11B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

First Light Asset Management deployed $73.1M of net new capital in Q2 2023, opening 6 new positions and adding to 21 existing holdings. Its largest new stake was Zentalis Pharmaceuticals: 757,835 shares worth $21.4M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 94% a quarter earlier, followed by Communication Services.

On the sell side, the largest reduction was Reata Pharmaceuticals, Inc. Class A Common Stock, an estimated $14.6M trimmed.

  • First Light Asset Management's largest Q2 2023 buy was Zentalis Pharmaceuticals: 757,835 shares worth $21.4M.
  • First Light Asset Management added most to Bicycle Therapeutics in Q2 2023, an estimated $24.2M increase.
  • First Light Asset Management's biggest Q2 2023 reduction was Reata Pharmaceuticals, Inc. Class A Common Stock, cutting an estimated $14.6M.
  • First Light Asset Management fully exited BELLUS Health Inc. in Q2 2023, selling an estimated $21.7M.
  • First Light Asset Management's ten largest holdings make up 53% of its $1.28B portfolio in Q2 2023.
  • First Light Asset Management opened 6 new positions and closed 1 in Q2 2023.
  • First Light Asset Management's portfolio value rose 15% quarter-over-quarter to $1.28B.

Based on First Light Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.